Skip to main content
SpringerLink
Log in

Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

Abstract

Dopamine agonists (DAs) represent a mainstay of therapy for hyperprolactinemia and prolactinomas. The widespread use of DAs, including bromocriptine, cabergoline and (in some countries) quinagolide, has led to the emergence and recognition of impulse control disorders (ICDs) that may occur in association with DA therapy.

Such ICDs include pathological gambling, compulsive shopping, hypersexuality and punding (the performance of repetitive tasks), among others. These manifestations can lead to substantial harms to patients and their families, if left undiagnosed and untreated. Several risk factors that may increase the risk of ICDs have been proposed, including younger age, male gender, smoking and alcohol use and history of depression.

The diagnosis of ICDs in hyperprolactinemic patients treated with DAs requires a high index of suspicion and a systematic approach, using available screening questionnaires. However, it should be noted that available test instruments, including questionnaires and computerized tasks, have not been validated specifically in hyperprolactinemic patients. Hyperprolactinemic patients who develop ICDs should be withdrawn from DA therapy or, at a minimum, undergo a DA dose reduction, and considered for psychiatric consultation and cognitive behavioral therapy. However, the role of psychopharmacotherapy in hyperprolactinemic patients with ICDs remains incompletely characterized.

Patient counseling regarding the risk of ICDs occurring in association with DA therapy, early detection and prompt intervention may mitigate potential harms associated with ICDs. Additional studies are needed to fully characterize risk factors, underlying mechanisms and identify effective therapies for ICDs in patients with hyperprolactinemia receiving DAs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Garcia-Ruiz PJ. Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. Front Neurol. 2018;9:1041. https://doi.org/10.3389/fneur.2018.01041.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Martini A, et al. Impulse Control Disorder in Parkinson’s Disease: A Meta-Analysis of Cognitive, Affective, and Motivational Correlates. Front Neurol. 2018;9:654. https://doi.org/10.3389/fneur.2018.00654.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Dang D, Cunnington D, Swieca J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol. 2011;34(2):66–70. https://doi.org/10.1097/WNF.0b013e31820d6699.

    Article  CAS  PubMed  Google Scholar 

  4. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52(8):2495–505. https://doi.org/10.1002/art.21191.

    Article  CAS  PubMed  Google Scholar 

  5. Ishida C, et al. Effectiveness of Levodopa in Patients with Multiple System Atrophy and Associated Clinicopathological Features. Intern Med. 2021;60(3):367–72. https://doi.org/10.2169/internalmedicine.4836-20.

    Article  PubMed  Google Scholar 

  6. Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol. 1983;13(3):273–8. https://doi.org/10.1002/ana.410130308.

    Article  CAS  PubMed  Google Scholar 

  7. Barake M, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. 2014;17(2):150–6. https://doi.org/10.1007/s11102-013-0480-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Barake M, Klibanski A, Tritos NA, MANAGEMENT OF ENDOCRINE DISEASE. Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry? Eur J Endocrinol. 2018;179(6):R287. https://doi.org/10.1530/EJE-18-0667.

    Article  CAS  PubMed  Google Scholar 

  9. Bakhshani NM. Impulsivity: a predisposition toward risky behaviors. Int J High Risk Behav Addict. 2014;3(2):e20428. https://doi.org/10.5812/ijhrba.20428.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chowdhury NS, et al. Pathological Gambling and Motor Impulsivity: A Systematic Review with Meta-Analysis. J Gambl Stud. 2017;33(4):1213–39. https://doi.org/10.1007/s10899-017-9683-5.

    Article  PubMed  Google Scholar 

  11. Antonelli F, et al. Dopamine-agonists and impulsivity in Parkinson’s disease: impulsive choices vs. impulsive actions. Hum Brain Mapp. 2014;35(6):2499–506. https://doi.org/10.1002/hbm.22344.

    Article  PubMed  Google Scholar 

  12. Weintraub D, Claassen DO. Impulse Control and Related Disorders in Parkinson’s Disease. Int Rev Neurobiol. 2017;133:679–717. https://doi.org/10.1016/bs.irn.2017.04.006.

    Article  PubMed  Google Scholar 

  13. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013;12(2):92–8. https://doi.org/10.1002/wps.20050.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kessler RC, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–27. https://doi.org/10.1001/archpsyc.62.6.617.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Perez-Lloret S, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261–5. https://doi.org/10.1097/WNF.0b013e31826e6e6d.

    Article  PubMed  Google Scholar 

  16. Bastiaens J, et al. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord. 2013;28(3):327–33. https://doi.org/10.1002/mds.25291.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Garcia-Ruiz PJ, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–4. https://doi.org/10.1136/jnnp-2013-306787.

    Article  PubMed  Google Scholar 

  18. Imamura A, et al. Medications used to treat Parkinson’s disease and the risk of gambling. Eur J Neurol. 2008;15(4):350–4. https://doi.org/10.1111/j.1468-1331.2008.02081.x.

    Article  CAS  PubMed  Google Scholar 

  19. Weintraub D, et al., Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol, 2010. 67(5): p. 589 – 95. https://doi.org/10.1001/archneurol.2010.65.

  20. Voon V, et al., Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology, 2010. 207(4): p. 645 – 59. https://doi.org/10.1001/archneurol.2010.65.

  21. Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci. 2007;19(4):473–4. https://doi.org/10.1176/jnp.2007.19.4.473.

    Article  PubMed  Google Scholar 

  22. Falhammar H, Yarker JY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust. 2009;190(2):97. https://doi.org/10.5694/j.1326-5377.2009.tb02289.x.

    Article  PubMed  Google Scholar 

  23. Martinkova J, et al. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011;34(5):179–81. https://doi.org/10.1097/WNF.0b013e3182281b2f.

    Article  CAS  PubMed  Google Scholar 

  24. Bancos I, et al. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):863–8. https://doi.org/10.1111/cen.12375.

    Article  Google Scholar 

  25. Celik E, et al. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine. 2018;62(3):692–700. https://doi.org/10.1007/s12020-018-1744-8.

    Article  CAS  PubMed  Google Scholar 

  26. Dogansen SC, et al. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. J Clin Endocrinol Metab. 2019;104(7):2527–34. https://doi.org/10.1210/jc.2018-02202.

    Article  PubMed  Google Scholar 

  27. Hinojosa-Amaya JM, et al. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. Front Endocrinol (Lausanne). 2020;11:579606. https://doi.org/10.3389/fendo.2020.579606.

    Article  Google Scholar 

  28. Ozkaya HM, et al. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. Growth Horm IGF Res. 2020;55:101356. https://doi.org/10.1016/j.ghir.2020.101356.

    Article  CAS  PubMed  Google Scholar 

  29. De Sousa SMC, et al., Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors. J Clin Endocrinol Metab, 2020. 105(3). https://doi.org/10.1210/clinem/dgz076.

  30. Beccuti G, et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J Endocrinol Invest. 2021;44(8):1699–706. https://doi.org/10.1007/s40618-020-01478-0.

    Article  CAS  PubMed  Google Scholar 

  31. Han JW, et al. Psychiatric Manifestation in Patients with Parkinson’s Disease. J Korean Med Sci. 2018;33(47):e300. https://doi.org/10.3346/jkms.2018.33.e300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24(15):2175–86. https://doi.org/10.1002/mds.22589.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Weintraub D, Papay K, Siderowf A. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology, 2013. 80(2): p. 176 – 80. https://doi.org/10.1212/WNL.0b013e31827b915c.

  34. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930–3. https://doi.org/10.1001/jamainternmed.2014.5262.

    Article  PubMed  Google Scholar 

  35. Eisenegger C, et al. Dopamine receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior. Biol Psychiatry. 2010;67(8):702–6. https://doi.org/10.1016/j.biopsych.2009.09.021.

    Article  CAS  PubMed  Google Scholar 

  36. Ziegler DA, et al. Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms. Scand J Psychol. 2014;55(3):278–86. https://doi.org/10.1111/sjop.12113.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Zainal Abidin S, et al. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson’s disease patients. BMC Neurol. 2015;15:59. https://doi.org/10.1186/s12883-015-0316-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Krishnamoorthy S, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson’s disease patients. Parkinsonism Relat Disord. 2016;30:13–7. https://doi.org/10.1016/j.parkreldis.2016.06.005.

    Article  PubMed  Google Scholar 

  39. Lee JY, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord. 2009;24(12):1803–10. https://doi.org/10.1002/mds.22678.

    Article  PubMed  Google Scholar 

  40. Castro-Martínez XH, et al. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. Parkinsonism Relat Disord. 2018;49:100–3. https://doi.org/10.1016/j.parkreldis.2018.01.010.

    Article  PubMed  Google Scholar 

  41. Vallelunga A, et al. Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2012;18(4):397–9. https://doi.org/10.1016/j.parkreldis.2011.10.019.

    Article  PubMed  Google Scholar 

  42. Parra-Díaz P, et al. Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review. Mov Disord Clin Pract. 2021;8(1):25–32. https://doi.org/10.1002/mdc3.13128.

    Article  PubMed  Google Scholar 

  43. Gahr M, Connemann BJ, Schönfeldt-Lecuona CJ. [Pathological gambling induced by dopamine agonists]. Fortschr Neurol Psychiatr. 2011;79(8):470–4. https://doi.org/10.1055/s-0031-1281580.

    Article  CAS  PubMed  Google Scholar 

  44. Almanzar S, Zapata-Vega MI, Raya JA. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. Psychosomatics. 2013;54(4):387–91. https://doi.org/10.1016/j.psym.2012.10.002.

    Article  PubMed  Google Scholar 

  45. Premaratne VS, Saeger I, Macdonald BK. Lesson of the month (1): cabergoline - ‘i eat funny on that’. Clin Med (Lond). 2014;14(2):205–7. https://doi.org/10.7861/clinmedicine.14-2-205.

    Article  Google Scholar 

  46. Bulwer C, et al. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clin Endocrinol (Oxf). 2017;86(6):862–4. https://doi.org/10.1111/cen.13339.

    Article  CAS  Google Scholar 

  47. Athanasoulia-Kaspar AP, Popp KH, Stalla GK. Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. Endocr Connect. 2018;7(2):R88-r94. https://doi.org/10.1530/EC-18-0030.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Thondam SK, et al. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clin Neuropharmacol. 2013;36(5):170–2. https://doi.org/10.1097/WNF.0b013e31829fc165.

    Article  CAS  PubMed  Google Scholar 

  49. Ke X, et al. The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study. BMC Endocr Disord. 2022;22(1):97. https://doi.org/10.1186/s12902-022-01009-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. De Sousa SM, et al. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine. 2017;55(2):618–24. https://doi.org/10.1007/s12020-016-1088-1.

    Article  CAS  PubMed  Google Scholar 

  51. Rawji V, et al. Ropinirole, a dopamine agonist with high D(3) affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults. Neuropharmacology. 2020;179:108278. https://doi.org/10.1016/j.neuropharm.2020.108278.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Wylie SA, et al. Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease. J Cogn Neurosci. 2012;24(8):1709–24. https://doi.org/10.1162/jocn_a_00241.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Mostofsky SH, Simmonds DJ. Response inhibition and response selection: two sides of the same coin. J Cogn Neurosci, 2008. 20(5): p. 751 – 61. https://doi.org/10.1162/jocn.2008.20500.

  54. Bellgrove MA, et al. Lateralized deficit of response inhibition in early-onset schizophrenia. Psychol Med. 2006;36(4):495–505. https://doi.org/10.1017/S0033291705006409.

    Article  PubMed  Google Scholar 

  55. Crosbie J, Schachar R. Deficient inhibition as a marker for familial ADHD. Am J Psychiatry. 2001;158(11):1884–90. https://doi.org/10.1176/appi.ajp.158.11.1884.

    Article  CAS  PubMed  Google Scholar 

  56. Garavan H, Hester R. The role of cognitive control in cocaine dependence. Neuropsychol Rev. 2007;17(3):337–45. https://doi.org/10.1007/s11065-007-9034-x.

    Article  PubMed  Google Scholar 

  57. Grall-Bronnec M, et al. Dopamine Agonists and Impulse Control Disorders: A Complex Association. Drug Saf. 2018;41(1):19–75. https://doi.org/10.1007/s40264-017-0590-6.

    Article  CAS  PubMed  Google Scholar 

  58. Solnick JV, et al. An experimental analysis of impulsivity and impulse control in humans. Learn Motiv. 1980;11(1):61–77. https://doi.org/10.1016/0023-9690(80)90021-1.

    Article  Google Scholar 

  59. Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69(4):183–9. https://doi.org/10.1002/syn.21805.

    Article  CAS  PubMed  Google Scholar 

  60. Balarajah S, Cavanna AE. The pathophysiology of impulse control disorders in Parkinson disease. Behav Neurol. 2013;26(4):237–44. https://doi.org/10.3233/BEN-2012-120266.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Matusiewicz AK, Reynolds B, Lejuez C. Assessment Instruments for Impulsivity and Impulse Control Disorders, The Oxford Handbook of Impulse Control Disorders. 2011, Oxford University Press. p. 0. https://doi.org/10.1093/oxfordhb/9780195389715.013.0141.

  62. Weintraub D, et al. Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale. Mov Disord. 2012;27(2):242–7. https://doi.org/10.1002/mds.24023.

    Article  PubMed  Google Scholar 

  63. Meyer B, Johnson SL, Carver CS. Exploring Behavioral Activation and Inhibition Sensitivities Among College Students at Risk for Bipolar Spectrum Symptomatology. J Psychopathol Behav Assess. 1999;21(4):275–92. https://doi.org/10.1023/A:1022119414440.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768–74. https://doi.org/10.1002/1097-4679(199511)51:6<768::aid-jclp2270510607>3.0.co;2-1.

    Article  CAS  PubMed  Google Scholar 

  65. Reid RC, Garos S, Carpenter BN. Reliability, Validity, and Psychometric Development of the Hypersexual Behavior Inventory in an Outpatient Sample of Men. Sex Addict Compulsivity. 2011;18(1):30–51. https://doi.org/10.1080/10720162.2011.555709.

    Article  Google Scholar 

  66. Reid RC, Garos S, Fong T. Psychometric development of the hypersexual behavior consequences scale. J Behav Addict. 2012;1(3):115–22. https://doi.org/10.1556/JBA.1.2012.001.

    Article  PubMed  Google Scholar 

  67. Lesieur HR, Blume SB. The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry. 1987;144(9):1184–8. https://doi.org/10.1176/ajp.144.9.1184.

    Article  CAS  PubMed  Google Scholar 

  68. Rao H, et al. Neural correlates of voluntary and involuntary risk taking in the human brain: an fMRI Study of the Balloon Analog Risk Task (BART). NeuroImage. 2008;42(2):902–10. https://doi.org/10.1016/j.neuroimage.2008.05.046.

    Article  PubMed  Google Scholar 

  69. Reynolds B, Schiffbauer R, Measuring state changes in human delay discounting: an experiential discounting task. Behav Processes, 2004. 67(3): p. 343 – 56. https://doi.org/10.1016/j.beproc.2004.06.003.

  70. Kharlip J, et al. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94(7):2428–36. https://doi.org/10.1210/jc.2008-2103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrine Unit and Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, 100 Blossom Street, Suite 140, 02114, Boston, MA, USA

    Anahid Hamidianjahromi MD & Nicholas A Tritos MD, DSc

  2. Harvard Medical School, Boston, MA, USA

    Nicholas A Tritos MD, DSc

Authors
  1. Anahid Hamidianjahromi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas A Tritos MD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas A Tritos MD, DSc.

Ethics declarations

Compliance with ethical standards and funding information

No external funding was used to support this manuscript.

Disclosure statement/conflict of interest

NAT has received institution-directed research support from Ipsen and Novartis and has served as an occasional consultant to Novo Nordisk and Pfizer. AH has nothing to disclose.

Informed consent and ethical approval

Informed consent and ethical approval were not obtained since the manuscript does not report on primary data.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamidianjahromi, A., Tritos, N.A. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord 23, 1089–1099 (2022). https://doi.org/10.1007/s11154-022-09753-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-022-09753-6

Keywords

Search

Navigation